marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-12-2024
Caladrius Biosciences Balance Sheet 2011-2024 | CLBS
Annual Balance Sheet Caladrius Biosciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-22.3 M | -31.7 M | -23.9 M | -15.9 M | -13.7 M | -10.3 M | -29 M | -7.91 M | -3.54 M | -2.53 M | -42 M | -9.92 M | 3.11 M |
Long Term Debt |
137 K | 305 K | 485 K | - | - | - | - | 2.82 M | 11.4 M | 14.7 M | 3.55 M | 172 K | - |
Long Term Debt Current |
168 K | 180 K | 229 K | 370 K | 354 K | - | - | 3.13 M | 4.17 M | 1.11 M | - | - | - |
Total Non Current Liabilities |
- | - | - | 254 K | 624 K | 1.51 M | 3.87 M | 28.3 M | 12.9 M | 52 M | 18 M | 11.6 M | 38.7 M |
Total Current Liabilities |
6.59 M | 6.38 M | 4.52 M | 3.51 M | 5.98 M | 5.62 M | 9.31 M | 19.5 M | 21 M | 16.2 M | 9.81 M | 9.95 M | 36.4 M |
Total Liabilities |
6.8 M | 6.71 M | 5.01 M | 3.76 M | 6.6 M | 7.13 M | 13.2 M | 47.8 M | 33.9 M | 68.2 M | 27.8 M | 21.6 M | 75.2 M |
Deferred Revenue |
- | - | - | - | - | - | - | 5.1 M | 5.35 M | 4.33 M | 1.82 M | 1.47 M | 2.44 M |
Retained Earnings |
-528 M | -507 M | -453 M | -426 M | -417 M | -398 M | -382 M | -405 M | -372 M | -291 M | -236 M | -197 M | -143 M |
Total Assets |
54.7 M | 73 M | 97 M | 36 M | 27.2 M | 44.6 M | 63.4 M | 51.8 M | 57.2 M | 126 M | 89.8 M | 54.4 M | 155 M |
Cash and Cash Equivalents |
22.6 M | 32.2 M | 24.6 M | 16.5 M | 14 M | 10.3 M | 29.2 M | 14.7 M | 20.3 M | 19.2 M | 46.1 M | 13.7 M | 3.94 M |
Book Value |
47.9 M | 66.3 M | 92 M | 32.2 M | 20.6 M | 37.5 M | 50.2 M | 4.07 M | 23.3 M | 58.1 M | 62 M | 32.8 M | 80.1 M |
Total Shareholders Equity |
48.1 M | 66.6 M | 92.3 M | 32.5 M | 20.8 M | 37.7 M | 50.5 M | 4.88 M | 23.7 M | 58.5 M | 62.5 M | 33.2 M | 62 M |
All numbers in USD currency
Quarterly Balance Sheet Caladrius Biosciences
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 47 K | 92 K | 137 K | 181 K | 223 K | 265 K | 305 K | 345 K | - | 421 K | 485 K | 53 K | 79 K | - | 254 K | 254 K | 254 K | - | - | - | - | - | - | - | - | - | - | - | - | 1.7 M | 2.52 M | 2.52 M | 2.52 M | 2.52 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 13.9 M | 13.9 M | 13.9 M | 13.9 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.4 M | - | - | - | 33.9 M | - | - | - | 68.2 M | - | - | 27.3 M | 27.8 M | 12.6 M | 12.2 M | 27.8 M | 21.6 M | 11.6 M | 11.6 M | 11.6 M | 33.9 M | 33.9 M | 33.9 M | 33.9 M |
Total Liabilities |
4.76 M | 4.58 M | 5.5 M | 6.8 M | 5.38 M | 4.65 M | 5.62 M | 6.71 M | 6.76 M | - | 3.22 M | 5.01 M | 4.12 M | 3.94 M | 4.59 M | 3.76 M | 3.76 M | 3.76 M | 3.76 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 7.13 M | 7.13 M | 7.13 M | 7.13 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 30 M | 30 M | 30 M | 28.4 M | 33.9 M | 64.7 M | 33.9 M | 33.9 M | 68.2 M | 69.3 M | 68.2 M | 68.2 M | 27.8 M | - | 27.8 M | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.58 M | - | - | - | 2.45 M | - | - | 5.36 M | 5.1 M | 5.87 M | 7.23 M | 5.64 M | 5.35 M | 5.35 M | 5.35 M | 5.35 M | 4.33 M | 4.33 M | 4.33 M | 4.33 M | 1.82 M | 1.82 M | 1.82 M | 1.82 M | 1.47 M | 1.47 M | 1.47 M | 1.47 M | 1.12 M | 1.12 M | 1.12 M | 2.44 M |
Retained Earnings |
-543 M | -539 M | -533 M | -528 M | -523 M | -517 M | -513 M | -507 M | -501 M | - | -457 M | -453 M | -446 M | -439 M | -434 M | -426 M | -426 M | -426 M | -426 M | -417 M | -417 M | -417 M | -417 M | -398 M | -398 M | -398 M | -398 M | -382 M | -382 M | -382 M | -382 M | -405 M | -405 M | -405 M | -405 M | -372 M | -372 M | -372 M | -372 M | -291 M | -291 M | -291 M | -291 M | -236 M | -236 M | -236 M | -236 M | -197 M | -197 M | -197 M | -197 M | -143 M | -143 M | -143 M | -143 M |
Total Assets |
38.2 M | 42.6 M | 48.2 M | 54.7 M | 58.1 M | 62.4 M | 66.3 M | 73 M | 78.5 M | - | 91.5 M | 97 M | 103 M | 109 M | 115 M | 36 M | 36 M | 36 M | 36 M | 27.2 M | 27.2 M | 27.2 M | 27.2 M | 44.6 M | 44.6 M | 44.6 M | 44.6 M | 63.4 M | 63.4 M | 63.4 M | 63.4 M | 53.5 M | 53.5 M | 53.5 M | 51.8 M | 57.2 M | 57.2 M | 57.2 M | 57.2 M | 126 M | 126 M | 126 M | 126 M | 89.8 M | 89.8 M | 89.8 M | 89.8 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 155 M | 155 M | 155 M | 155 M |
Cash and Cash Equivalents |
19.5 M | 28.3 M | 21.8 M | 22.6 M | 32.4 M | 23.7 M | 28.2 M | 32.2 M | 31.5 M | 33.3 M | 12.7 M | 24.6 M | 12.8 M | 12.9 M | 28.7 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 14 M | 14 M | 14 M | 14 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 29.2 M | 29.2 M | 29.2 M | 29.2 M | 7.08 M | 7.08 M | 7.08 M | 14.7 M | 18.7 M | 20.3 M | 20.3 M | 20.3 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 46.1 M | 46.1 M | 46.1 M | 46.1 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 3.94 M | 3.94 M | 3.94 M | 12.6 M |
Book Value |
33.4 M | 38 M | 42.7 M | 47.9 M | 52.7 M | 57.7 M | 60.7 M | 66.3 M | 71.8 M | - | 88.2 M | 92 M | 98.4 M | 105 M | 110 M | 32.2 M | 32.2 M | 32.2 M | 32.2 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 37.5 M | 37.5 M | 37.5 M | 37.5 M | 50.2 M | 50.2 M | 50.2 M | 50.2 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 23.3 M | -7.5 M | 23.3 M | 23.3 M | 58.1 M | 57 M | 58.1 M | 58.1 M | 62 M | 89.8 M | 62 M | 89.8 M | 54.4 M | 54.4 M | 54.4 M | 54.4 M | 155 M | 155 M | 155 M | 155 M |
Total Shareholders Equity |
33.7 M | 38.2 M | 43 M | 48.1 M | 52.7 M | 57.7 M | 60.7 M | 66.6 M | 71.8 M | 82.1 M | 88.2 M | 92.3 M | 98.4 M | 105 M | 110 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | 37.7 M | 37.7 M | 37.7 M | 37.7 M | 50.5 M | 50.5 M | 50.5 M | 50.5 M | 4.88 M | 4.88 M | 4.88 M | 4.88 M | 23.7 M | 23.7 M | 23.7 M | 23.7 M | 58.5 M | 58.5 M | 58.5 M | 58.5 M | 62.5 M | 62.5 M | 62.5 M | 62.5 M | 33.2 M | 33.2 M | 33.2 M | 33.2 M | 62 M | 62 M | 62 M | 62 M |
All numbers in USD currency